NCT06634589 2026-03-18A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesBeOne MedicinesPhase 1/2 Recruiting80 enrolled